Dostinex Valvular Heart Disease lawsuit

Schmidt & Clark, LLP is No Longer Taking These Cases - If you feel that you may have a potential case, we urge you to contact another law firm adequately suited to handle your case.

Dostinex (cabergoline) has recently been linked to valvular heart disease involving one or more valves and a host of other extremely serious heart-related health conditions. Valvular heart disease is life-threatening, and typically requires heart valve replacement surgery to correct the problem. If you have been injured by the side effects of Dostinex, you may be entitled to compensation for your pain and suffering.

What’s the problem?

Manufactured by Pfizer, Dostinex is a prescription drug used in the treatment of certain hormone problems involving excess prolactin. Dostinex is also commonly used to treat Parkinson’s disease, prolactin-producing tumors, and to adjust various hormone levels in certain diseases (ovarian diseases). Unfortunately, increasing evidence and at least two scholarly studies have linked Dostinex to valvular heart disease in an abnormally high number of patients.

Pergolide was withdrawn from the U.S. market in 2006 after two studies published in the New England Journal Of Medicine (NEJM) found that approximately 25% of patients taking the drug had moderate to severe heart valve problems. Users of Dostinex were reportedly 5 to 7 times more likely to have leaky heart valves than those on other similar medications. According to the study results:

“In conclusion, our study showed that treatment with either pergolide or cabergoline, particularly at daily doses greater than 3 mg and for periods of 6 months or longer, was associated with a substantially increased risk of newly diagnosed cardiac-valve regurgitation. There was no evidence of such an increase with the use of other dopamine agonists.”

Awards & recognition